Anti-FcGR3A (CD16A) IgG Antibody, Biotin-Labeled

Fc Gamma Receptor IIIa (FcGR3A) is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, antibody-dependent cytotoxicity, and clearance of immune complexes. FcGR3A plays a role in the activation of natural killer (NK) cells. Clinically, it serves as a marker of certain immune cells such as neutrophils. CD16 expression has been observed at the surface of T cells in patients with chronic viral infections (such as COVID-19) . It is considered a potential therapeutic target to potentiate the efficacy of therapeutic antibodies used to treat solid tumors, or as direct target in hematopoietic cancers.